Shaping the Future of Clinical Trial Innovation

The Association of American Cancer Institutes (AACI) Clinical Research Innovation (CRI) program serves as a network for research leaders to develop and share best practices for the efficient operation of clinical trials offices (CTO) at AACI cancer centers. The programming of the 18th Annual AACI CRI Meeting, “Shaping the Future of Clinical Trial Innovation,” aims to stimulate cancer center interactions and maximize resources by creating opportunities for peer-to-peer networking and collaboration.

Meeting Objectives

• Apply real-world data and AI tools to improve cancer clinical trial feasibility, patient recruitment, and equity
• Streamline cancer clinical trial start-up, enhance communication, and accelerate study activation without compromising quality
• Support staff readiness, retention, and operational excellence in CTOs through training, onboarding, and mentorship
• Align cross-departmental workflows to ensure regulatory and operational consistency in complex clinical trials
• Learn budgeting, reimbursement, and funding models to maintain compliance, long-term sustainability, and data integrity in CTOs
• Explore industry–cancer center collaborations to expand patient inclusion, decentralize trials, and improve reimbursement models in clinical research
• Identify key features of efficient multisite cancer trials, including standardized operations, principal investigator oversight, and investigational drug logistics

Who Should Attend

• Individuals from AACI member cancer centers, including:
  • CTO administrative directors, medical directors, managers, and supervisors
  • Deputy/associate directors of clinical research administration
  • Cancer center administrators
  • Research regulatory managers and staff
  • Clinical research finance directors, managers, and supervisors
  • Biostatisticians and informatics specialists
• Employees of U.S. Department of Health and Human Services agencies and offices, including the National Cancer Institute and the U.S. Food and Drug Administration
• AACI Sustaining Members
• AACI Corporate Roundtable members
• Representatives from industry, including drug development companies, clinical research organizations, and consultants
• Information technology companies that support cancer center clinical research management
• Like-minded organizations promoting patient access to clinical trials